mTOR AMPK Muscle Catabolism
TL;DR
mTORC1 and AMPK are opposing master regulators of muscle protein synthesis and breakdown. During caloric deficit — whether from diet, GLP-1 therapy, or aging — AMPK activation suppresses mTORC1, reducing muscle protein synthesis. Resistance training is the primary tool to preferentially activate mTORC1 in a catabolic environment, because mechanical tension signals through mTORC1 even when amino acid and insulin signals are blunted.
Why this matters for Vitals
- GLP-1 therapy interpretation: Lean mass loss during Retatrutide/tirzepatide is a direct consequence of this pathway in caloric deficit. HRV suppression during GLP-1 therapy may reflect catabolic stress at the cellular energy level.
- Protein intake coaching: 2.0–2.5 g/kg/day is justified by the need to keep amino acid signaling as high as possible given AMPK-mediated mTORC1 suppression.
- Wearable readiness: Sustained HRV depression without identifiable confounders (illness, alcohol, travel) during active weight loss may reflect AMPK activation and catabolic state — not just training load.
- Detection logic: There is no direct wearable signal for mTOR/AMPK state. This is mechanistic inference context, not a detection call.
Core biology
mTORC1 — the anabolic switch
Primary activators:
- Amino acids (particularly leucine) → Rag GTPases → mTORC1 translocation to lysosome
- Mechanical tension / resistance training → PI3K-Akt → mTORC1
- Insulin / IGF-1 → Akt → mTORC1
Primary inhibitors:
- AMPK (energy deficit sensor)
- REDD1 (hypoxia, stress)
- ATF4 (integrated stress response)
Net effect: mTORC1 activation → ribosomal biogenesis + muscle protein synthesis (MPS)
AMPK — the catabolic switch
Primary activators:
- Rising AMP:ATP ratio (energy deficit)
- Exercise (particularly aerobic — Contributes to energy deficit locally in muscle)
- Low glycogen states
Primary effects:
- Directly phosphorylates mTORC1 → inhibits it
- Phosphorylates ULK1 → promotes autophagy
- Inhibits glycogen synthesis
- Promotes fatty acid oxidation
Net effect: Catabolism and energy conservation
The caloric deficit problem
During negative energy balance:
| Signal | Direction | Reason |
|---|---|---|
| Amino acids | ↓ to normal | Reduced protein synthesis from food |
| Insulin/IGF-1 | ↓ | Reduced caloric intake |
| AMPK | ↑ | Rising AMP:ATP from energy deficit |
| Mechanical tension | Variable | Depends on training |
The combination of ↓ amino acid signaling + ↓ insulin + ↑ AMPK creates strong mTORC1 suppression. This is why even 2.3–3.1 g protein/kg during caloric restriction shows lean mass loss in 9/13 study groups (PMID:24092765).
Resistance training in caloric deficit
Why it partially rescues mTORC1:
Mechanical tension activates mTORC1 through a pathway partially independent of amino acids and insulin:
- Load sensing → mechanosensor → mTORC1 pathway
- Tension activates PI3K-Akt axis even without high insulin
- Muscle damage activates repair cascades that upregulate protein synthesis
Evidence: Meta-analysis shows resistance training 3×/week during caloric restriction shifts lean fraction from ~26% to ~17.5% of total weight lost (PMID:39295512). It does not eliminate lean loss — it reduces it.
Limitation: Mechanical signaling alone cannot fully overcome the AMPK-driven mTORC1 suppression from sustained energy deficit. Some lean loss is inevitable at large caloric deficits.
mTORC1 + AMPK relationship to other Vitals mechanisms
| Compound or Intervention | Interaction with mTOR/AMPK |
|---|---|
| Rapamycin | Direct mTORC1 inhibitor — opposite direction from resistance training; prevents muscle hypertrophy even with training |
| SLU-PP-332 (ERR agonist) | Activates PGC-1α; may support mitochondrial biogenesis without mTORC1 inhibition; complementary to resistance training |
| GLP-1 therapy (Retatrutide, tirzepatide) | Not a direct mTOR/AMPK modulator; creates caloric deficit → ↑AMPK/↓mTORC1 indirectly |
| Exercise Mimetics | AMPK activators or mTOR modulators — see Exercise Mimetics |
| Autophagy | AMPK → ULK1 → autophagy — upregulated during caloric deficit; see Autophagy |
| Mitophagy | Mitochondrial quality control during energy stress; see Mitophagy |
Important nuances
Preclinical vs. human: The mTOR/AMPK pathway is evolutionarily conserved; basic science is strong. Human translation is well-established for resistance training effects but less precise for pharmacologic targeting.
This is not GLP-1 specific: The same pathway governs muscle loss during any sustained caloric deficit — bariatric surgery, non-pharmacologic dieting, cancer cachexia, aging sarcopenia. GLP-1 therapy is not unique in this mechanism; it is unique in the rapidity and magnitude of weight loss achievable.
Bimagrumab works upstream of this pathway through ActRII blockade → ↓Smad2/3 → relief of mTORC1 inhibition — see ActRII Myostatin Pathway.
Related notes
- ActRII Myostatin Pathway — Smad2/3 arm of muscle catabolism; complementary to AMPK/mTORC1; bimagrumab mechanism
- GLP-1 Muscle Preservation — the hub note; GLP-1 therapy creates the caloric deficit that activates this pathway
- Retatrutide — Ben’s GLP-1/GIP/GCGR agonist
- Exercise Mimetics — pharmacologic approaches to AMPK/mTOR modulation
- Autophagy — AMPK → ULK1 → autophagy upregulation during energy deficit
- Mitophagy — mitochondrial quality control during metabolic stress
- Resistance Training for Longevity — mTORC1 activation as anchor mechanism for resistance training benefits
Source: PMID:24092765 (protein during caloric restriction) · PMID:39295512 (muscle loss minimization strategies) · general muscle metabolism literature